Charnwood Molecular

Operating from state-of-the-art research facilities in Loughborough and BioCity Nottingham, UK, we are a leading Contract Research Organisation, providing medicinal and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

The cornerstone of our success is built upon regular and open communication with our clients, the highest integrity in our business relationships, high quality yet cost effective services, and the flexibility that we offer – we can undertake projects from one week in duration to multi-year, multi-FTE collaborations. Our goal is to support you in producing excellence in your own research, achieving your milestones and business objectives on time and to budget.

We offer a range of competitively priced services tailored to the specific requirements of our clients. These include Medicinal Chemistry and Contract Research (FTE). 

Medicinal Chemistry
Charnwood Molecular offers support to drug discovery efforts within the pharmaceutical and biotechnology industries. This service covers Lead Discovery and Lead Optimisation. Our pharma-trained medicinal chemists have experience in many therapeutic areas.

Contract Research
Presented with a target molecule with little or no literature precedent, we will investigate potential methods of preparation, optimisation and scale-up, according to your needs.

Company Type
Twitter Account
@charnwoodmol

Club Quarters Hotels

Club Quarters Hotels are full service hotels located in world-class cities in the U.S. and London. Designed for business and urban travelers, we have the accommodations, amenities and services needed to make your stay productive, enjoyable, and hassle-free.

Company Type
Keywords
Twitter Account
@ClubQuarters

Curileum Discovery

Curileum Discovery Ltd is a new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.

We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.

Company Type
Twitter Account
@curileum

Cytoseek Limited

CytoSeek's mission is to use Artificial Membrane Binding Protein technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours. 

The company was founded in November 2017 to commercialise the technology developed by Professor Adam Perriman and his team at the University of Bristol.

CytoSeek is now engaged in proof of principle studies for multiple product candidates, and is seeking to enhance cell therapies against solid tumours.

Twitter Account
@CYTOSEEK